Literature DB >> 32295333

[Chinese guidelines on the treatment of hemophilia (version 2020)].

.   

Abstract

Entities:  

Year:  2020        PMID： 32295333     DOI： 10.3760/cma.j.issn.0253-2727.2020.04.001

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN： 0253-2727


× No keyword cloud information.
  5 in total

Review 1.  Congenital hemophilia A with low activity of factor XII: a case report and literature review.

Authors:  Baoyu Lei; Chuang Liang; Haiyan Feng
Journal:  Ital J Pediatr       Date:  2021-10-11       Impact factor: 2.638

2.  Medical costs and hospital utilization for hemophilia A and B urban inpatients in China: a national cross-sectional study.

Authors:  Zhengwei Huang; Stephen Nicholas; Yong Yang; Xiaoping Chen; Elizabeth Maitland; Yong Ma; Xuefeng Shi
Journal:  BMC Health Serv Res       Date:  2022-02-19       Impact factor: 2.655

3.  Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.

Authors:  Rong Chen; Dmitry Gultyaev; Johanna Lister; Rong Han; Nan Hu; Jean Malacan; Alexander Solms; Parth Vashi; Jamie O'Hara; Shanlian Hu
Journal:  BMC Med Res Methodol       Date:  2022-08-05       Impact factor: 4.612

Review 4.  Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.

Authors:  Jing Sun; Xuan Zhou; Nan Hu
Journal:  Orphanet J Rare Dis       Date:  2021-06-26       Impact factor: 4.123

5.  [Perioperative application of recombinant human coagulation factor Ⅶa combined with prothrombin complex in two hemophilia A patients with high titer inhibitor].

Authors:  P P Xu; H Zhou; P Zhang; J Q Wang; L Liu; C Li; M J Li; G P Li; B J Ding; J P Liu; X R Wang; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-09-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.